Study | Year | Selection (0–4) | Comparability (0–2) | Outcome (0–3) | Total |
---|
REC | SNEC | AE | DO | SC | AF | AO | FU | AFU |
---|
Konczalla L | 2019 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 6 |
Woestemeier A | 2018 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 6 |
Tanaka M | 2015 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 7 |
Matsushita D | 2015 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 6 |
Reeh M | 2015 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 6 |
Sclafani F | 2014 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 4 |
Hiraiwa K | 2008 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 4 |
- Abbreviations: REC Representativeness of the exposed cohort, SNEC Selection of the nonexposed cohort, AE Ascertainment of exposure, DO Demonstration that outcome of interest was not present at start of study, SC Study controls for age, sex, AF Study controls for any additional factors (chemoradiotherapy, curative resection), AO Assessment of outcome, FU Follow-up long enough (36 M) for outcomes to occur, AFU Adequacy of follow-up of cohorts (≥90%). “1” means that the study is satisfied the item and “0” means the opposite situation